Rexahn Pharmaceuticals Company Profile

08:54 EST 21st November 2017 | BioPortfolio

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system disorders and other unmet medical needs. Our motto is "Saving Lives Through Innovation," which represents the Company's use of scientific innovation to improve the health and wellness of patients. We develop therapies that treat specific disease states, while minimizing side effects in order to help patients regain quality of life during treatment. Rexahn currently has a number of drug candidates in clinical development for cancer, CNS related disorders and sexual dysfunction. The Company's lead cancer candidate, Archexin (formerly named RX-0201) successfully completed Phase I clinical trials in 2006 and is in Phase II clinical trials for patients with advanced stage renal cell carcinoma (RCC), an abnormal growth of cells lining the tubules of the kidney. Additional Archexin clinical trials in gastrointestinal (GI) indications, such as pancreatic and stomach cancers, will follow. In the CNS area, Rexahn's drug candidate, Serdaxin for anxiety, and Zoraxel for sexual dydsfunction will enter Phase II clinical trials in 2007. Based on early studies, the compound appears to act on serotonin and dopamine, which are key neurotransmitters in the brain implicated in both of these conditions.


9620 Medical Center Drive
United States of America


Phone: 240-268-5300
Fax: 240-268-5310

News Articles [469 Associated News Articles listed on BioPortfolio]

Rexahn Pharmaceuticals: Saving Lives Through Innovation

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Rick Soni, Chief Operating Officer at Rexahn Pharmaceuticals, an innovative biopharmaceutical company. They discuss...

Rexahn Pharmaceuticals, Inc. Announces $8 Million Registered Direct Offering

ROCKVILLE, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN) today announced it has entered into definitive agreements with institutional investors to purchase...

RDO nets $7.5mm for Rexahn

Rexahn Pharmaceuticals Inc. (oncology) netted $7.5mm through a registered direct offering of 3.6mm common shares at $2.45 (an 8% discount) to institutional investors. The company also issued five-year...

Rexahn Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial And Operational Results

ROCKVILLE, Md., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment...

Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the t...

Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC

ROCKVILLE, Md., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the tr...

Rexahn Pharmaceuticals, Inc. Receives New U.S. Patent For Supinoxin

  Life Sciences Jobs   ...

Rexahn Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

Presented Preliminary Clinical Efficacy Data on RX-3117 in Bladder Cancer and Final Data on the Supinoxin™ Phase I Study at the ESMO Congress Strengthened Patent Position on RX-3117 and Supinox...

Drugs and Medications [270 Associated Drugs and Medications listed on BioPortfolio]

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

Eyewash station additive concentrate [Niagara Pharmaceuticals Inc.]


PubMed Articles [120 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Effects of exposure to pharmaceuticals (diclofenac and carbamazepine) spiked sediments in the midge, Chironomus riparius (Diptera, Chironomidae).

Human and veterinary pharmaceuticals and degradation products are continuously introduced into the environment. To date, there is a lack of information about the effects of pharmaceuticals in spiked t...

Clinical Trials [206 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Bioequivalence Study of Hydrochlorothiazide 50mg Tablets Under Fasting Conditions

To compare the single-dose oral bioavailability of hydrochlorothiazide 50 mg tablet of Ohm Laboratories (A subsidiary of Ranbaxy pharmaceuticals USA) with hydrochlorothiazide 50 mg tablet ...

Companies [1287 Associated Companies listed on BioPortfolio]

Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disord...

Rexahn Pharmaceuticals

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system disorders...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Rexahn Pharmaceuticals" on BioPortfolio

We have published hundreds of Rexahn Pharmaceuticals news stories on BioPortfolio along with dozens of Rexahn Pharmaceuticals Clinical Trials and PubMed Articles about Rexahn Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Rexahn Pharmaceuticals Companies in our database. You can also find out about relevant Rexahn Pharmaceuticals Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Corporate Database Quicklinks

Searches Linking to this Company Record